Crispr Therapeutics Stock Been: A Roller-Coaster Year Unpacked
CRISPR Therapeutics stock has zigzagged all year, driven by pipeline milestones, regulatory updates, and funding need...
Learn when bonds may outperform stocks for retirement, with practical timing cues and risk considerations.
24,889 articlesCRISPR Therapeutics stock has zigzagged all year, driven by pipeline milestones, regulatory updates, and funding need...
An oversized insider trade at Check Point Software followed a sharp stock decline. Learn how to interpret this move, ...
As earnings season looms, Monday’s best Wall Street calls are guiding early moves in key names. Traders watch multipl...
Tesla reports a record-breaking Q2, delivering 480,126 vehicles and signaling renewed momentum. Regional strength in ...
Richtech Robotics faced a sharp pullback in early 2026, driven by execution missteps and market concerns. This piece ...
Bridger Management quietly exited a large Bath & Body Works position in the fourth quarter, selling about 301,000 sha...
When a beverage maker expands beyond a single hero brand, the investment narrative changes. Celsius transformed its g...
A major family-office investor has increased its position in Middleby as the company prepares a spin-off. This move o...
Palantir stock surged as global tensions flare and AI-driven defense angles capture headlines. Yet investors should b...
Trump signals possible U.S. ground action against Mexican cartels, sending ripples through defense stocks and supply ...
Capricor is at a crossroads as 2026 earnings season unfolds. This article breaks down what to look for in capricor (c...
Stocks edge higher as Nvidia earnings loom, lifting the S&P 500 and Nasdaq. This stock market live 2026 update tracks...